DE60137540D1 - Methoden zur behandlung von angstzuständen - Google Patents

Methoden zur behandlung von angstzuständen

Info

Publication number
DE60137540D1
DE60137540D1 DE60137540T DE60137540T DE60137540D1 DE 60137540 D1 DE60137540 D1 DE 60137540D1 DE 60137540 T DE60137540 T DE 60137540T DE 60137540 T DE60137540 T DE 60137540T DE 60137540 D1 DE60137540 D1 DE 60137540D1
Authority
DE
Germany
Prior art keywords
alkyl
radical
methods
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60137540T
Other languages
English (en)
Inventor
Mark Robert Bowlby
Sharon Joy Rosenzweig-Lipson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Application granted granted Critical
Publication of DE60137540D1 publication Critical patent/DE60137540D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60137540T 2000-12-20 2001-12-19 Methoden zur behandlung von angstzuständen Expired - Fee Related DE60137540D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25683400P 2000-12-20 2000-12-20
PCT/US2001/049362 WO2002049628A2 (en) 2000-12-20 2001-12-19 Methods of treating anxiety disorders

Publications (1)

Publication Number Publication Date
DE60137540D1 true DE60137540D1 (de) 2009-03-12

Family

ID=22973775

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60137540T Expired - Fee Related DE60137540D1 (de) 2000-12-20 2001-12-19 Methoden zur behandlung von angstzuständen

Country Status (9)

Country Link
US (1) US6589986B2 (de)
EP (1) EP1343495B1 (de)
JP (1) JP2004518653A (de)
AT (1) ATE421321T1 (de)
AU (1) AU2002231122A1 (de)
CA (1) CA2431278A1 (de)
DE (1) DE60137540D1 (de)
MX (1) MXPA03005497A (de)
WO (1) WO2002049628A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080898A2 (en) * 2001-04-04 2002-10-17 Wyeth Methods for treating hyperactive gastric motility
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
EP1578740B1 (de) 2002-12-27 2007-03-21 H. Lundbeck A/S 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
PL377221A1 (pl) * 2002-12-27 2006-01-23 H. Lundbeck A/S Pochodne 1,2,4-triaminobenzenu
MXPA05010000A (es) 2003-03-21 2005-11-17 Lundbeck & Co As H Derivados de p-diaminobenceno substituidos.
AU2004233941A1 (en) * 2003-04-25 2004-11-11 H. Lundbeck A/S Sustituted indoline and indole derivatives
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
TWI357901B (en) 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati
EP2298766B1 (de) 2005-03-03 2013-09-18 H. Lundbeck A/S Pharmazeutische Formulierungen mit einem substituierten Pyridinderivat
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
AU2007288253B2 (en) * 2006-08-23 2013-05-02 Xenon Pharmaceuticals Inc. Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
BRPI0719590A2 (pt) * 2006-11-28 2014-01-21 Valeant Pharmaceuticals Int Análogos de retigabina 1,4 diamino bicíclica como modulares de canal de potássio
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
EP2203411B1 (de) 2007-09-20 2016-01-06 Ramot at Tel-Aviv University Ltd. N-phenylanthranilsäurederivate und anwendungen davon
AU2009270768A1 (en) * 2008-07-18 2010-01-21 Valeant Pharmaceuticals International Modified release formulation and methods of use
MX2014013166A (es) * 2012-04-30 2015-05-11 Scifluor Life Sciences Llc Derivados de 2-amino-4-(bencilamino)fenilcarbamato fluorados.
US10526280B2 (en) 2014-11-13 2020-01-07 University of Pittsburgh—of the Commonwealth System of Higher Education (2-amino-4-(arylamino)phenyl carbamates
WO2019203951A1 (en) 2018-04-20 2019-10-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Selective potassium channel agonists
WO2021113802A1 (en) * 2019-12-06 2021-06-10 Icahn School Of Medicine At Mount Sinai Method of treatment with kcnq channel openers
WO2021211867A1 (en) * 2020-04-16 2021-10-21 Attune Neurosciences, Inc. Kv7 modulators for treating sleep or anxiety disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
DE19539861A1 (de) 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
DE19701694A1 (de) 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
GB9915414D0 (en) 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US6495550B2 (en) 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
AU779034B2 (en) 1999-08-04 2005-01-06 Icagen, Inc. Benzanilides as potassium channel openers
BR0012934A (pt) 1999-08-04 2003-07-29 Icagen Inc Processos para a redução de dor e de ansiedade
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain

Also Published As

Publication number Publication date
US6589986B2 (en) 2003-07-08
US20020111379A1 (en) 2002-08-15
EP1343495B1 (de) 2009-01-21
MXPA03005497A (es) 2003-10-06
CA2431278A1 (en) 2002-06-27
JP2004518653A (ja) 2004-06-24
WO2002049628A3 (en) 2002-10-17
ATE421321T1 (de) 2009-02-15
WO2002049628A2 (en) 2002-06-27
EP1343495A2 (de) 2003-09-17
AU2002231122A1 (en) 2002-07-01

Similar Documents

Publication Publication Date Title
DE60137540D1 (de) Methoden zur behandlung von angstzuständen
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
WO2003043961A3 (en) Modulators of rho c activity
DK0775129T3 (da) 3-Benzoylbenzofuranderivater som thyroidhormonantagonister
RS67204A (en) Tripeptides having a hydroxyproline ether of a substituted quinoline for inhibition of ns3 (hepatitis c)
ATE306916T1 (de) Neue fettanaloge zur behandlung von sekundärer restenose
BR0211078A (pt) Compostos, processo papa a preparação e uso dos mesmos, composições herbicidas, e, método para o controle de ervas daninhas em áreas cultivadas
YU57603A (sh) Inhibitori fosfodiesteraze 4
PE20010964A1 (es) Derivados de tiazolilamida
UY25143A1 (es) Procedimiento para la preparacion de inhibidores de proteasas.
IL160045A0 (en) Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues
EP0959906A4 (de)
DE3853577T2 (de) Benzyliden-Malononitril-Derivate zur Hemmung von proliferativen Prozessen in Säugetierzellen.
EP2289887A3 (de) Epoxidcarboxylsäureamide, Azide und Aminoalkohole sowie Verfahren zur Herstellung von Alpha-Ketoamiden damit
DE60210960D1 (de) Carbamat-verbindungen zur prävention oder behandlung von angstzuständen
DE69006452T2 (de) Derivate und Analoge von Pyrimidon zur Behandlung von Asthma und bestimmte Hautkrankheiten.
BR9606429A (pt) Composto composição e processo para tratamento de disfunção mediada por uPar- ou uPa-
WO2002074777A3 (en) Pyranocoumarin compounds as a novel pharmacophore with anti-tb activity
BR0116721A (pt) Processo para a preparação de (±)-trans-4-p-fluorofenil-3-hidroximetil-1-metilpiperi dina
ATE232202T1 (de) Verfahren zur herstellung von n-(2- (dimethylamino)ethyl)akridin-4-carbonsäureamide
BR9809685B1 (pt) mistura fungicida, processo para controlar fungos nocivos, uso de um composto, e, composição.
ATE264840T1 (de) Azetidincarboxamid-derivate zur behandlung von zns störungen
DE69006471T2 (de) Phenylacetonitrilalkylaminoalkyl-(ortho-substituierte)-Arylverbindungen als Immunosupressoren.
WO2002088091A3 (en) Inhibitors of human rhinovirus 2a cysteine protease
EA200200540A1 (ru) Щелочные соли n-(6-алкил-2,4-диоксо-1,2,3,4-тетрагидро-5-пиримидинсульфон)-n&#39;-изоникотиноилгидразида, которые могут обладать антимикробной и иммунотропной активностью, способ их получения, их использование в качестве иммуномодулятора и фармацевтическая композиция на их основе

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee